Jackisch, Christian

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 5,084

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 2,659

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 2,157

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 351

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer

Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment

Cited by 138

The patient’s anastrozole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer

Hadji, P., Blettner, M., Harbeck, N., Jackisch, C., Lück, H.-J., Windemuth-Kieselbach, C., Zaun, S., & Kreienberg, R. (2013) · Annals of Oncology

Medication Adherence and ComplianceCancer survivorship and care

Cited by 122

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., et al. (2015) · Annals of Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 114

Subcutaneous Administration of Monoclonal Antibodies in Oncology

Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014) · Geburtshilfe und Frauenheilkunde

Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research

Cited by 90

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

Jackisch, C., Stroyakovskiy, D., Pivot, X., Ahn, J. S., Melichar, B., Chen, S.-C., Meyenberg, C., Al-Sakaff, N., Heinzmann, D., & Hegg, R. (2019) · JAMA Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 84

Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers

Jackisch, C., Müller, V., Dall, P., Neumeister, R., Park-Simon, T.-W., Ruf-Dördelmann, A., Seiler, S., Tesch, H., & Ataseven, B. (2015) · Geburtshilfe und Frauenheilkunde

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 42

Towards an early warning system for monitoring of cancer patients using hybrid interactive machine learning

Trojan, A., Laurenzi, E., Jüngling, S., Roth, S., Kiessling, M., Atassi, Z., Kadvany, Y., Mannhart, M., Jackisch, C., Kullak-Ublick, G., et al. (2024) · Frontiers in Digital Health

Artificial Intelligence in HealthcareMobile Health and mHealth Applications

Cited by 10

Subcutaneous Injection of Trastuzumab – Analysis of Administration Time and Injection Site Reactions

Pivot, X., Semiglazov, V., Chen, S., Moodley, S. D., Manihkas, A., Coccia-Portugal, M. A., Johnston, M., van der Horst, T., Bouhlel, A., & Jackisch, C. (2012) · Annals of Oncology

Intramuscular injections and effectsHER2/EGFR in Cancer Research

Cited by 8